Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania

被引:26
作者
Janavicius, Ramunas [1 ,2 ]
Rudaitis, Vilius [3 ,4 ]
Mickys, Ugnius [5 ]
Elsakov, Pavel [2 ,6 ]
Griskevicius, Laimonas [1 ,3 ]
机构
[1] Vilnius Univ Hosp Santariskiu Klin, Dept Mol & Regenerat Med, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania
[2] Innovat Med Ctr, State Res Inst, Vilnius, Lithuania
[3] Vilnius Univ, Fac Med, Clin Internal Family Med & Oncol, Vilnius, Lithuania
[4] Vilnius Univ Hosp Santariskiu Klin, Ctr Womens Physiol & Pathol, Dept Gynecol, Vilnius, Lithuania
[5] Natl Ctr Pathol, Vilnius, Lithuania
[6] Publ Inst Ctr Poliklin, Vilnius, Lithuania
关键词
BRCA1; BRCA2; hereditary breast and ovarian cancer; genetic testing; oncogenetics; REDUCING SALPINGO-OOPHORECTOMY; OVARIAN-CANCER FAMILIES; BREAST-CANCER; FOUNDER MUTATIONS; BREAST/OVARIAN CANCER; GENE-MUTATIONS; HIGH-FREQUENCY; EARLY-ONSET; RISK; WOMEN;
D O I
10.1016/j.cancergen.2014.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is limited knowledge about the BRCA1/2 mutational profile in Lithuania. We aimed to define the full BRCA1 and BRCA2 mutational spectrum and the clinically relevant prevalence of these gene mutations in Lithuania. A data set of 753 unrelated probands, recruited through a clinical setting, was used and consisted of 380 female breast cancer cases, 213 epithelial ovarian cancer cases, 20 breast and ovarian cancer cases, and 140 probands with positive family history of breast or ovarian cancer. A comprehensive mutation analysis of the BRCA1/2 genes by high resolution melting analysis coupled with Sanger sequencing and multiplex ligation-dependent probe amplification analysis was performed. Genetic analysis revealed 32 different pathogenic germline BRCA1/2 mutations: 20 in the BRCA1 gene and 12 in the BRCA2 gene, including four different large genomic rearrangements in the BRCA1 gene. In all, 10 novel BRCA1/2 mutations were found. Nine different recurrent BRCA1 mutations and two recurrent BRCA2 mutations were identified, which comprised 90.4% of all BRCA1/2 mutations. BRCA1 exon 1-3 deletion and BRCA2 c.658_659del are reported for the first time as recurrent mutations, pointing to a possible Baltic founder effect. Approximately 7% of breast cancer and 22% of ovarian cancer patients without family history and an estimated 0.5-0.6% of all Lithuanian women were found to be carriers of mutations in the BRCA1 or BRCA2 gene.
引用
收藏
页码:195 / 205
页数:11
相关论文
共 55 条
[1]  
[Anonymous], CLIN PRACT GUID ONC
[2]   The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions [J].
Antoniou, A. C. ;
Cunningham, A. P. ;
Peto, J. ;
Evans, D. G. ;
Lalloo, F. ;
Narod, S. A. ;
Risch, H. A. ;
Eyfjord, J. E. ;
Hopper, J. L. ;
Southey, M. C. ;
Olsson, H. ;
Johannsson, O. ;
Borg, A. ;
Passini, B. ;
Radice, P. ;
Manoukian, S. ;
Eccles, D. M. ;
Tang, N. ;
Olah, E. ;
Anton-Culver, H. ;
Warner, E. ;
Lubinski, J. ;
Gronwald, J. ;
Gorski, B. ;
Tryggvadottir, L. ;
Syrjakoski, K. ;
Kallioniemi, O-P ;
Eerola, H. ;
Nevanlinna, H. ;
Pharoah, P. D. P. ;
Easton, D. F. .
BRITISH JOURNAL OF CANCER, 2008, 98 (08) :1457-1466
[3]   BRCA in breast cancer: ESMO Clinical Recommendations [J].
Balmana, J. ;
Diez, O. ;
Castiglione, M. .
ANNALS OF ONCOLOGY, 2009, 20 :19-20
[4]   High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland [J].
Brozek, Izabela ;
Ochman, Karolina ;
Debniak, Jaroslaw ;
Morzuch, Lucyna ;
Ratajska, Magdalena ;
Stepnowska, Magdalena ;
Stukan, Maciej ;
Emerich, Janusz ;
Limon, Janusz .
GYNECOLOGIC ONCOLOGY, 2008, 108 (02) :433-437
[5]   Prevalence of the most frequent BRCA1 mutations in Polish population [J].
Brozek, Izabela ;
Cybulska, Celina ;
Ratajska, Magdalena ;
Piatkowska, Magdalena ;
Kluska, Anna ;
Balabas, Aneta ;
Dabrowska, Michalina ;
Nowakowska, Dorota ;
Niwinska, Anna ;
Pamula-Pilat, Jolanta ;
Tecza, Karolina ;
Pekala, Wioletta ;
Rembowska, Jolanta ;
Nowicka, Karina ;
Mosor, Maria ;
Januszkiewicz-Lewandowska, Danuta ;
Rachtan, Jadwiga ;
Grzybowska, Ewa ;
Nowak, Jerzy ;
Steffen, Jan ;
Limon, Janusz .
JOURNAL OF APPLIED GENETICS, 2011, 52 (03) :325-330
[6]   Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer [J].
Byrski, Tomasz ;
Dent, Rebecca ;
Blecharz, Pawel ;
Foszczynska-Kloda, Malgorzata ;
Gronwald, Jacek ;
Huzarski, Tomasz ;
Cybulski, Cezary ;
Marczyk, Elzbieta ;
Chrzan, Robert ;
Eisen, Andrea ;
Lubinski, Jan ;
Narod, Steven A. .
BREAST CANCER RESEARCH, 2012, 14 (04)
[7]   Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis [J].
Carvalho, Marcelo A. ;
Marsillac, Sylvia M. ;
Karchin, Rachel ;
Manoukian, Siranoush ;
Grist, Scott ;
Swabym, Ramona F. ;
Urmenyi, Turan P. ;
Rondinelli, Edson ;
Silva, Rosane ;
Gayol, Luis ;
Baumbach, Lisa ;
Sutphen, Rebecca ;
Pickard-Brzosowicz, Jennifer L. ;
Nathanson, Katherine L. ;
Sali, Andrej ;
Goldgar, David ;
Couch, Fergus J. ;
Radice, Paolo ;
Monteiro, Alvaro N. A. .
CANCER RESEARCH, 2007, 67 (04) :1494-1501
[8]  
Csokay B, 1999, HUM MUTAT, V14, P92
[9]   Hereditary breast cancer: from bench to bedside [J].
De Greve, Jacques ;
Sermijn, Erica ;
De Brakeleer, Sylvia ;
Ren, Zhuo ;
Teugels, Erik .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) :605-613
[10]   Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: Comparison of two high-resolution melting platforms [J].
De Leeneer, Kim ;
Coene, Ilse ;
Poppe, Bruce ;
De Paepe, Anne ;
Claes, Kathleen .
CLINICAL CHEMISTRY, 2008, 54 (06) :982-989